Literature DB >> 27236112

Circulating regulatory T cells in patients with aortic valve stenosis: Association with disease progression and aortic valve intervention.

Sara Shimoni1, Iris Bar2, Valery Meledin2, Gera Gandelman2, Jacob George2.   

Abstract

BACKGROUND: Severe aortic valve stenosis (AS) accounts for considerable morbidity and death, especially in older patients. There is increasing evidence to suggest a role for immune modulating cells in aortic valve (AV) degeneration. Regulatory T cells (Tregs) tune down inflammation. We aimed to study the levels of circulating Tregs in patients with AS and to assess their association with disease progression. METHOD AND
RESULTS: The number of Tregs (CD4+CD25+Foxp3+) was determined by flow cytometry in 229 patients with AS and a control group of 69 patients. Tregs were significantly higher in patients with AS compared to the control group (1.64± .61% vs 1.13±0.97%, p=0.04). In the logistic regression analysis, adjusted for baseline characteristics, only the hemoglobin level and Treg percent correlated with the presence of AS (OR 0.642 95% CI 0.512-0.805, p<0.001 and OR 1.411, 95% CI 1.080-1.844, p=0.011, respectively). One hundred patients underwent 2 echocardiographic studies during follow-up. The median decrease in AV area (AVA) was 0.1cm(2)/year. A borderline association was observed between Tregs and AVA progression (r=0.19, p=0.054). In a subgroup of 68 patients with severe AS, the association between Tregs and AVA progression was significant (r=0.374, p=0.0017). In addition, a drop in Treg levels was observed 3-6months after AV-intervention (1.86±1.6% vs 1.04±1.8%, p=0.0005).
CONCLUSIONS: Circulating Tregs are elevated in patients with AS. The levels of Tregs are higher in patients with severe AS and accelerated progression of valve narrowing. These results may help to identify AS patients with accelerated disease progression and possibly in need for earlier intervention.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Aortic valve stenosis; Immune system; Progression; Regulatory T cells

Mesh:

Year:  2016        PMID: 27236112     DOI: 10.1016/j.ijcard.2016.05.039

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

Review 1.  Innate and adaptive immunity: the understudied driving force of heart valve disease.

Authors:  Francesca Bartoli-Leonard; Jonas Zimmer; Elena Aikawa
Journal:  Cardiovasc Res       Date:  2021-11-22       Impact factor: 10.787

Review 2.  Adaptive immune cells in calcific aortic valve disease.

Authors:  Michael A Raddatz; Meena S Madhur; W David Merryman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-03       Impact factor: 4.733

Review 3.  Innate and adaptive immunity in cardiovascular calcification.

Authors:  Livia S A Passos; Adrien Lupieri; Dakota Becker-Greene; Elena Aikawa
Journal:  Atherosclerosis       Date:  2020-02-28       Impact factor: 5.162

4.  Advances in Pathophysiology of Calcific Aortic Valve Disease Propose Novel Molecular Therapeutic Targets.

Authors:  Alexia Hulin; Alexandre Hego; Patrizio Lancellotti; Cécile Oury
Journal:  Front Cardiovasc Med       Date:  2018-03-14

Review 5.  Involvement of inflammatory responses in the early development of calcific aortic valve disease: lessons from statin therapy.

Authors:  Seung Hyun Lee; Jae-Hoon Choi
Journal:  Anim Cells Syst (Seoul)       Date:  2018-09-28       Impact factor: 1.815

6.  TLR7 Expression Is Associated with M2 Macrophage Subset in Calcific Aortic Valve Stenosis.

Authors:  Glykeria Karadimou; Oscar Plunde; Sven-Christian Pawelzik; Miguel Carracedo; Per Eriksson; Anders Franco-Cereceda; Gabrielle Paulsson-Berne; Magnus Bäck
Journal:  Cells       Date:  2020-07-16       Impact factor: 6.600

7.  Inflammatory and immune checkpoint markers are associated with the severity of aortic stenosis.

Authors:  Bilguun Erkhem-Ochir; Wataru Tatsuishi; Takehiko Yokobori; Tsukasa Ohno; Kyohei Hatori; Tadashi Handa; Tetsunari Oyama; Ken Shirabe; Hiroshi Saeki; Tomonobu Abe
Journal:  JTCVS Open       Date:  2020-11-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.